ABOS
NASDAQ
US
Acumen Pharmaceuticals, Inc. - Common Stock
$2.70
▲ +$0.15
(+5.88%)
Vol 636K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$127.8M
ROE
-97.4%
Margin
-509.7%
D/E
32.90
Beta
0.24
52W
$1–$2
Wall Street Consensus
12 analysts · Apr 20266
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
91.7%
Buy Rating
Price Chart
Similar Stocks
PRLD
Prelude Therapeutics Inc
$164.2M
ARTV
Artiva Biotherapeutics Inc
$105.3M
RNAC
Cartesian Therapeutics Inc
$187.5M
WHWK
Whitehawk Therapeutics Inc
$114.1M
NKTX
Nkarta Inc
$131.4M
VTVT
vTv Therapeutics Inc
$167.1M
KALA
KALA BIO Inc
$12.2M
IMUX
Immunic Inc
$64.2M
TNYA
Tenaya Therapeutics Inc
$154.0M
HRTX
Heron Therapeutics Inc
$238.4M
Earnings
Beat rate: 60.0%
Next Report
May 11, 2026
EPS Estimate: $-0.40
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.40 | — | — |
| Dec 2025 | $-0.46 | $-0.41 | +$0.05 |
| Sep 2025 | $-0.62 | $-0.44 | +$0.18 |
| Jun 2025 | $-0.55 | $-0.68 | $-0.13 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$29.8M | -$37.2M | -$28.8M | -$41.0M | -$26.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -81.4% | -81.4% | -81.4% | -81.4% | -97.4% | -97.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -509.7% | -509.7% | -509.7% | -509.7% | -509.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 25.52 | 25.52 | 25.52 | 25.52 | 32.90 | 32.90 |
| Current Ratio | 5.97 | 5.97 | 5.97 | 5.97 | 6.02 | 6.02 |
Key Ratios
ROA (TTM)
-70.4%
P/S (TTM)
88.76
P/B
0.6
EPS (TTM)
$-2.21
CF/Share
$-1.10
52W High
$2.46
52W Low
$0.86
$0.86
52-Week Range
$2.46
Financial Health
Free Cash Flow
-$30.5M
Net Debt
-$16.0M
Cash
$46.8M
Total Debt
$30.8M
As of Sep 30, 2025
How does ABOS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ABOS valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
88.8
▲
591%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.6
▼
77%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ABOS profitability vs Biotechnology peers
ROE
-97.4%
▼
45%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-509.7%
▼
78%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-70.4%
▼
51%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
ABOS financial health vs Biotechnology peers
D/E ratio
32.9
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
6.0
▲
36%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
0.2
▼
75%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ABOS fundamentals radar
ABOS
Peer median
Industry
ABOS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ABOS vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
RA CAPITAL MANAGEMENT, L.P.
Beneficial Owner of more than… · Mar 16
6060606 shs
MEISNER DEREK M
Officer · Mar 06
2090 shs
MEISNER DEREK M
Officer · Mar 06
2090 shs
MEISNER DEREK M
Officer · Feb 27
9406 shs
MEISNER DEREK M
Officer · Feb 27
9406 shs
MEISNER DEREK M
Officer · Jan 28
17756 shs
MEISNER DEREK M
Officer · Jan 28
17756 shs
MEISNER DEREK M
Officer · Jan 23
8934 shs
WILLIAM MATTHEW ZUGA
Chief Financial Officer · Jan 22
4160 shs
O'CONNELL DANIEL JOSEPH
Chief Executive Officer · Jan 22
12035 shs
Last 90 days
Top Holders
Top 5: 40.18%RA Capital Management, L.P.
24.65%
$33.7M
Sands Capital Alternatives,…
5.64%
$7.7M
Franklin Resources, Inc.
3.81%
$5.2M
FMR, LLC
3.35%
$4.6M
Vanguard Group Inc
2.73%
$3.7M
As of Dec 31, 2025
Latest News
No related news yet